JW Pharmaceutical Holds 'Jeicle' Symposium at Korean Society of Coloproctology Spring Conference

by Kwak Minjae

Published 09 Mar.2026 09:26(KST)

JW Pharmaceutical announced on March 9 that it held a symposium for the colon cleansing agent 'Jeicle' on March 8 during the 47th Spring Conference of the Korean Society of Coloproctology, which took place at Lotte Hotel Seoul in Sogong-dong, Seoul.

JW Pharmaceutical held a symposium for the colon cleansing agent "J-Cle" on the 8th at the 47th Spring Academic Conference of the Korean Society of Gastrointestinal Endoscopy, held at Lotte Hotel Seoul in Sogong-dong, Seoul. JW Pharmaceutical

At the symposium, Professor Park Soobum from the Department of Gastroenterology at Yangsan Pusan National University Hospital participated as a speaker, presenting the results of the Phase 3 clinical trial for Jeicle and discussing its application as a bowel preparation before colonoscopy.

Jeicle tablet is a prescription medication taken to cleanse the colon prior to various diagnostic procedures such as endoscopy and X-ray imaging. It is characterized by its convenient dosing-requiring only 20 tablets in total-and its film-coated formulation, which makes swallowing easier and enhances patient compliance.

In particular, traditional powder or liquid-type colon cleansing agents have sometimes led to adverse reactions such as nausea and headaches during administration, increasing patient burden or negatively impacting diagnostic accuracy. In contrast, the tablet form reduces adverse events and provides superior convenience for patients.

The main ingredients of Jeicle include magnesium sulfate, potassium sulfate, and sodium sulfate, which act as osmotic laxatives; simethicone, which eliminates bubbles in the colon; and sodium picosulfate, which promotes colonic peristalsis.

During the lecture, Professor Park explained that the results of the Phase 3 clinical trial showed Jeicle tablet was equivalent to the control group in terms of colon cleansing efficacy, safety, and medication adherence.

Professor Park stated, "The Phase 3 results showed no statistically significant difference in colon cleansing efficacy between the Jeicle group and the control group based on the Harefield Cleansing Scale (HCS), and the rates of polyp and adenoma detection were also similar. Additionally, the incidence of adverse reactions such as nausea and headaches was lower in the Jeicle group compared to the control group."

According to the Phase 3 clinical results, the incidence of nausea was 21.7% in the control group versus 7.62% in the Jeicle group, and the incidence of headaches was 8.49% in the control group compared to just 0.95% in the Jeicle group, as reported by the company.

Professor Park added, "With the addition of simethicone, almost no bubbles were observed during the examination, making the product very useful, and the film-coated tablet is easy to swallow, so patients undergoing colonoscopy tended to feel less burdened and showed a preference for this option."

These Phase 3 clinical results were recently published in the SCI (Science Citation Index) international journal 'World Journal of Gastroenterology.'

JW Pharmaceutical plans to expand clinical experience with Jeicle by providing product information based on clinical results in the future.

A JW Pharmaceutical official stated, "Through this symposium, we shared the results of the Phase 3 trial and practical application points for Jeicle with medical professionals. We will continue to promote options that consider both the needs of healthcare providers for pre-colonoscopy bowel preparation and patient convenience."